It is reported that "Jianjia robot" has recently completed a round B financing of more than 100 million yuan. This round of financing is jointly invested by Hillhouse venture capital, Fosun Pharmaceutical and the old shareholder bv Baidu venture capital. Haoyue capital continues to serve as the exclusive financial adviser for this round of financing. This is a new round of financing for "Jianjia robot" after a round of financing of tens of millions of yuan in early 2020. This round of funds will be used to promote the clinical registration and new product R & D of the company's existing joint replacement surgical robot.
"Jianjia robot", fully known as Hangzhou Jianjia robot Co., Ltd., was established in 2018. The company is committed to the independent innovation, R & D and production of intelligent orthopaedic surgical robot, as well as providing the market with accurate joint replacement scheme, covering the whole process of "preoperative, intraoperative and postoperative".
According to the analysis on the development status and future development potential of the global and Chinese medical robot industry in 2020, the scale of China's robot market reached US $8.68 billion in 2019, and the average growth rate from 2014 to 2019 reached 20.9%. Among them, the service robot is US $2.2 billion. The scale of China's medical robot market exceeds US $600 million in 2019, is expected to reach US $740 million in 2020, and will exceed US $1 billion by 2021.
At present, more than 40 enterprises in China have set foot in the field of medical robots. In 2019, nearly half of medical robot enterprises obtained financing, with a total amount of more than 400 million yuan. Under the influence of favorable policies, aging, increasing consumer groups and accelerating industrialization, China's medical robot market is in a stage of rapid growth.
Forecast of China's medical robot market scale from 2016 to 2021
Financing of medical robot industry in 2014-2019
At present, "Jianjia robot" has independently developed the hip replacement surgery robot artrobot. Artrobot not only realizes the accurate positioning, grinding and prosthesis installation of the acetabular side, but also covers the treatment of the femoral side, controls the final surgical error within 1mm and the installation angle deviation within 1 °, and significantly improves the clinical pain points of poor surgical accuracy of hip replacement, long doctor learning curve and perennial intraoperative radiation exposure.
"A lot of evidence shows that minimally invasive joint replacement surgery significantly shortens the time of hospitalization, rehabilitation and social reintegration of patients, resulting in a reduction in medical costs," said the person in charge of Fosun Pharmaceutical Jianjia project. With the assistance of joint surgery robot, it is expected to overcome the artificial uncertainty of joint replacement in minimally invasive environment and realize the consistency of surgical effect. "
The person in charge of BV Baidu venture capital said: "the intelligent surgical robot system, as a new capability platform to improve the quality and efficiency of surgery, has proved its great potential in clinic, and will further expand its capability boundary with the rapid development of AI perception, computing and work technology. With the aggravation of social aging and the increasing demand of orthopaedic market, orthopaedic surgical robot system has great market potential. In recent years, national policies have strongly encouraged and supported the innovation of domestic medical devices. We believe that this is an excellent layout opportunity. "
